6 recent pharma industry exec moves

More posts on drug store: Moderna on track to report initial vaccine data next monthGileads earnings increases by 17%, driven by remdesivir salesRegeneron says its COVID-19 antibody cocktail reveals guarantee in mild to moderate cases.

Canadian drugmaker Algernon Pharmaceuticals selected Mark Swaim, MD, PhD, to its medical and clinical advisory board Oct. 9.

Katie Adams –
Friday, October 30th, 2020
Print|Email.

Luciano Rossetti, MD, revealed his retirement Oct. 15 from his role as international head of research and advancement for Mercks health care business sector.

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by click on this link.

Rick Bright, PhD, a vaccine expert with years of experience working in the federal government, resigned from HHS Oct. 6 pointing out a hostile office.

Reno, Nev.-based Renown Health called Adam Porath, PharmD, its vice president of drug store Oct. 16.

Bayer selected Christian Rommel, PhD, as its new head of pharmaceuticals research study and advancement Oct. 27.

Below are six executive management modifications affecting the pharmaceutical market that were announced in October.

Thomas Aasen signed up with the board of directors for North Carolina drugmaker Evecxia Therapeutics Oct. 28.